Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (143)	10/22/1998
From: David Cathcart	Read Replies (1) \| Respond to of 1073

Rick, <<The thought was floated (not by you) in the MOGN thread that the Europe deal would be sealed by the time phase II trials were initiated. Didn't happen.>> Almost a year ago Blitzer said during a presentation that he expected to complete the European deal around the beginning of the phase II. I passed that comment along on the MOGN thread. As you point out the deal hasn't happened yet. Blitzer was wrong and perhaps silly to boot. The efficacy that Richard points out seems to me to be more important than the conversation about the Europe deal. If the drug is working, how important is it for the European deal to be competed now? If the drug continues to work, won't the European deal and a lot of other problems solve themselves? Am I seeing significance that is not there in the efficacy results revealed in the high dose patients in the phase I trial? Particularly in the case of the pancreatic patient. David

To: scaram(o)uche who wrote (143)	10/22/1998 7:48:00 AM
From: David Cathcart	Read Replies (1) \| Respond to of 1073

Rick, <<Has Blitzer pointed anyone to preclinical toxicology data?>> I'm not familiar with this toxicology data. Perhaps I missed an earlier post but are there danger signs here? Thanks. David

To: scaram(o)uche who wrote (143)	10/22/1998 10:55:00 AM
From: David Cathcart	Read Replies (1) \| Respond to of 1073

Rick, Richard Bagnell pointed out that MGI Pharma is conducting their own phase II trials for MGI 114 for prostrate, ovarian and pancreatic cancer. The National Cancer Institute in presently conducting phase II MGI 114 trials for non-small cell lung cancer, metastatic kidney cancer and colon cancer, plus a phase I pediatric study for recurrent or refractory solid tumors. To see the current NCI MGI 114 trials progress, go to the NCI PDQ® Clinical Trials Search Form at: cancernet.nci.nih.gov Type “MGI” in the drug field of the search form and it will bring up the current MGI 114 trials they are sponsoring. My understanding is that the NCI plans to add eight additional phase II MGI 114 trials in the coming weeks (months?). David